Mats Wahlstrom Purchases 5,000 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Director Mats Wahlstrom acquired 5,000 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The shares were acquired at an average cost of $4.55 per share, for a total transaction of $22,750.00. Following the acquisition, the director now directly owns 15,727 shares of the company’s stock, valued at $71,557.85. This trade represents a 46.61 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

Mats Wahlstrom also recently made the following trade(s):

• On Wednesday, November 20th, Mats Wahlstrom bought 2,040 shares of TriSalus Life Sciences stock. The shares were bought at an average price of $4.16 per share, for a total transaction of $8,486.40.

TriSalus Life Sciences Price Performance

Shares of NASDAQ TLSI opened at $4.32 on Wednesday. The company has a 50-day simple moving average of $4.24 and a 200-day simple moving average of $5.49. The company has a market cap of $131.73 million, a PE ratio of -1.73 and a beta of 0.49. TriSalus Life Sciences, Inc. has a 12 month low of $3.61 and a 12 month high of $10.42.

Institutional Trading of TriSalus Life Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Walleye Capital LLC purchased a new position in shares of TriSalus Life Sciences during the 3rd quarter worth $66,000. Virtu Financial LLC purchased a new position in TriSalus Life Sciences during the third quarter worth about $92,000. Vestcor Inc purchased a new position in TriSalus Life Sciences during the third quarter worth about $108,000. MSD Partners L.P. acquired a new stake in TriSalus Life Sciences in the 3rd quarter worth about $184,000. Finally, Wolverine Asset Management LLC purchased a new stake in TriSalus Life Sciences in the 2nd quarter valued at about $240,000. 2.58% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Roth Mkm began coverage on shares of TriSalus Life Sciences in a research report on Monday, November 11th. They set a “buy” rating and a $11.00 price target for the company. Oppenheimer started coverage on shares of TriSalus Life Sciences in a research note on Monday, September 16th. They issued an “outperform” rating and a $10.00 price objective on the stock. Northland Securities assumed coverage on shares of TriSalus Life Sciences in a research report on Friday, October 25th. They set an “outperform” rating and a $12.50 target price for the company. Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Finally, Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, TriSalus Life Sciences has an average rating of “Buy” and an average price target of $12.08.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.